Trinasolar Unveils High-Power i-TOPCon Ultra Modules at Korea's Green Energy Expo
DAEGU, South Korea, April 22, 2025 /PRNewswire/ -- Trinasolar, a global leader in smart PV and energy storage solutions, unveiled its revolutionary i‑TOPCon Ultra technology at Korea's Green Energy Expo in Daegu. This next-generation solar solution pushes the boundaries of efficiency and reliability, achieving a record laboratory cell efficiency of 26.58%. This marks the first time the cell 26.5% efficiency threshold has been surpassed TOPCon history, breaking the seven-year record previously held by Germany's Fraunhofer Institute.
Technological Superiority Designed for Optimal LCOE
The i‑TOPCon Ultra technology represents a significant evolution in photovoltaic design. By integrating double-sided full passivation, mitigating optical parasitic absorption, and utilizing ultra‑thin busbar technology, the new modules boost cell efficiency by up to 1%, with enhanced module power output of up to 40W. For example, the Vertex N medium-size bifacial dual glass module for commercial and industrial applications (NEG19RC.20) will boast remarkable efficiency of 23.9% and maximum power output of 645W. The larger-sized bifacial dual glass module for utility applications (NEG21C.20) offers an output of 740W and efficiency of 23.8%.
Tailored for the Korean Market
Korea's diverse and challenging weather conditions demand robust and high‑performance solar technology. Trinasolar's modules undergo rigorous testing with global institutes like TÜV Rheinland. This includes extreme temperatures (as low as –43°C), 35mm hail impact, hurricane (wind tunnel) tests, and in high‑salt marine environments. This resilience ensures that Trinasolar's modules can deliver consistent, long‑term energy yields while reducing the lifetime operational expenses for local projects.
Li Na, General Manager for Korea at Trinasolar Asia Pacific said, "As Korea drives toward its renewable energy goals of 20% by renewable energy share by 2030, Trinasolar will continue to bring the latest in technological advancements to empower the nation's energy future. As we enter the era of tandem cells, the synergy of TOPCon and perovskite tandem technology will be a powerful force, ensuring that TOPCon maintains its dominant position as a mainstream technology. With our latest Ultra modules, Trinasolar reaffirms its commitment to supporting Korea's sustainable energy transformation with high efficiency and high-powered modules specifically engineered to meet the rigorous demands of the Korean market."
Besides its state-of-the-art modules, Trinasolar will also be showcasing its latest Elementa 2 Pro 5MWh battery energy storage solution, also for the first time in Korea. The Elementa 2 Pro builds on the success of Elementa 2, offering even greater efficiency, flexibility, and safety. The Elementa 2 Pro features Trina's self-developed 314Ah high-performance Trina Cell, supporting 15,000 cycles (up from 12,000 cycles offered in Elementa 2) to significantly extend system lifespan and reduce lifecycle costs, ensuring a higher return on investment for users. It offers enhanced advanced cooling technology, incorporating an intelligent hybrid air-liquid cooling system.
Visit Trinasolar at Booth E300 to explore how we are empowering Korea's renewable energy transition as the industry's only total solutions provider. From industry-leading n-type i-TOPCon modules to advanced energy storage solutions, Trinasolar delivers market-leading technologies designed to optimize LCOE for projects of all scales.
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/trinasolar-unveils-high-power-i-topcon-ultra-modules-at-koreas-green-energy-expo-302425518.html
SOURCE Trina Solar Energy Development Pte. Ltd.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
China Matters' Feature: Low-altitude Economy -- A New Industry Reshaping Global Transportation
BEIJING, June 10, 2025 /PRNewswire/ -- From electric vehicles (EVs) to the 4,500-kilometer high-speed railway network that accounts for two thirds of the global total, China is forging a connected world with its outstanding strength. In the field of transportation, China is pioneering a brand-new frontier: the low-altitude economy. To put it in a simpler way, vehicles can transform into flying machines to facilitate people's daily travels. In the future, flying taxis, delivery drones, and airborne adventures are poised to redefine transportation. With the emergence of such companies as DJI drone, China accounts for over 70% of global civilian drone sales. EHang, a Guangzhou-based tech pioneer, has become the world's first company to secure full aviation certifications for its passenger-carrying flying vehicles. The market value of China's low-altitude economy skyrocketed to over $70 billion in 2023, achieving an impressive annual growth rate of 33.8%. What's more, a new low-altitude route between Shenzhen and Zhuhai cuts the three-hour drive down to a 20-minute flight. Faster, more affordable, and with Instagram-worthy views: this is how urban mobility is redefining itself. None of this would be possible without cutting-edge technology. With 5G-Advanced networks tracking aircrafts in real-time, drones can now help plant crops, deliver packages, aid disaster relief operations. This sector's rapid growth highlights its potential to reshape logistics, tourism, and emergency services, signaling vast economic opportunities. Technological advancements in renewable energy, Al, and telecommunications have accelerated the development of low-altitude technologies, while government support and private investments fuel the progress of the entire industry. By integrating radar systems, 5G networks, and Al-driven monitoring, China aims to build a secure, efficient low-altitude ecosystem for future generations. Click the link below to know more about this new technology. Stay tuned for more exciting content coming soon. YouTube Link: View original content to download multimedia: SOURCE China Matters Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
CGTN: China-U.S. trade talks in London receive positive market reception
With the first meeting of the China-U.S. economic and trade consultation mechanism set to continue in London on Tuesday, CGTN publishes an article discussing the significance of the highly anticipated talks and the global expectations surrounding them. The article also highlights China's attitude and stance on the trade talks, stressing the importance of China-U.S. cooperation in achieving mutually beneficial outcomes. BEIJING, June 10, 2025 /PRNewswire/ -- The first meeting of the China-U.S. economic and trade consultation mechanism is set to continue on Tuesday in London with a second day of talks. The gathering of key officials from the world's two largest economies is widely seen as a crucial step in easing tensions between the two countries, sending a positive signal to the global economy. The highly anticipated trade talks come just days after a phone call between Chinese President Xi Jinping and U.S. President Donald Trump. They are aimed at implementing the consensus reached by both leaders and continuing to foster dialogue and cooperation in economic and trade fields. Chinese Vice Premier He Lifeng is leading the Chinese delegation in London, while U.S. Treasury Secretary Scott Bessent, Commerce Secretary Howard Lutnick and Trade Representative Jamieson Greer are heading the U.S. team. Severe economic repercussions The London talks are a direct outcome of the Geneva discussions in May, when both sides agreed to pause the escalating tariffs and establish a consultation mechanism to continue negotiations. The Geneva meeting featured the first face-to-face talks between senior officials from both nations since the U.S. imposed hefty tariffs on China in April, and China retaliated with robust countermeasures. The tariff hikes have not only hurt the global supply chain, but also harmed the U.S. economy, driving up costs, reducing consumption and increasing the risk of economic recession. A Harris Poll conducted for Bloomberg News in late May revealed that many Americans are tightening their belts, a recent survey by Bank of America showed that allocations to U.S. assets are at their lowest levels in nearly two decades, and multiple sources, including U.S. Bank, JP Morgan and the International Monetary Fund, have suggested a 40 percent chance of a U.S. recession. Cooperation is the only way out Given these concerning economic repercussions, Xi has stressed that dialogue and cooperation are the only correct choice for the two countries. He hailed the Geneva talks as an important step forward in resolving disputes and urged the two sides to make good use of the economic and trade consultation mechanism and seek win-win results in the spirit of equality and respect for each other's concerns. The Chinese side is sincere about this, and at the same time has its principles, Xi said. The positive market reactions mirrored Xi's remarks and reflected growing optimism about the easing of China-U.S. trade frictions. Following the leaders' phone talks, shipping demand surged, leading to a spike in freight rates, and U.S. stock indices saw substantial gains, with the S&P 500, Nasdaq and Dow Jones all experiencing significant increases. Wu Zewei, a special researcher at Sushang Bank, said the London talks are expected to boost the prospects for bilateral cooperation. He stated that though the negotiations in London will not be easy and require in-depth discussions, the Geneva talks have laid a strong foundation for cooperation and the recent phone call between the two heads of state has provided direction for future negotiations. "The cooperation between China and the U.S. has significant potential. In the future, both countries can still achieve mutual benefit and win-win outcomes, fostering shared prosperity and creating a better life for their peoples," said Wu. View original content: SOURCE CGTN Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Kelun-Biotech Announces Breakthrough Therapy Designation Granted for Sacituzumab Tirumotecan (Sac-TMT) in Combination With Tagitanlimab in China for Certain Types of Non-Small Cell Lung Cancer
CHENGDU, China, June 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) (佳泰莱®) in combination with the PD-L1 monoclonal antibody tagitanlimab (科泰莱®) was granted Breakthrough Therapy Designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without actionable genomic alterations. Breakthrough Therapy Designation is granted for treatment options that demonstrate significant clinical advantages over currently available treatments and is aimed at expediting the research, development and marketing of innovative treatment options that address clinically urgent medical needs. This designation is based on the efficacy and safety data from the non-squamous cohort of the Phase II OptiTROP-Lung01 study. This marks the fifth Breakthrough Therapy Designation granted to sac-TMT by the NMPA. Sac-TMT has previously received this designation for: Locally advanced or metastatic triple-negative breast cancer (TNBC) in July 2022; EGFR-mutant, locally advanced or metastatic NSCLC after progression on EGFR-TKI therapy in January 2023; Locally advanced or metastatic hormone-receptor positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC) in patients who have previously received at least two lines of systemic chemotherapy in June 2023； First-line treatment of unresectable locally advanced, recurrent or metastatic PD-L1 negative TNBC in March 2024. Results from a Phase 2 OptiTROP-Lung01 study of sac-TMT in combination with tagitanlimab in first-line advanced or metastatic non-squamous NSCLC patients were presented in a poster session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting[1]. Dr. Michael Ge, CEO of Kelun-Biotech said, "This designation by the NMPA highlights the importance of developing novel therapeutic options for diverse NSCLC subtypes. Sac-TMT in combination with tagitanlimab demonstrated clinically meaningful outcomes in key endpoints for patients with non-squamous NSCLC without actionable genomic alterations as a first-line treatment. We are excited about the therapeutic potential of TROP2 ADC- immunotherapy combinations, and we look forward to working with regulatory authorities in China to bring this combination therapy to patients in need as soon as possible." [1] Abstract #8529: Lung Cancer – Non-Small Cell Metastatic, ASCO Annual Meeting, 2025 About sac-TMT (佳泰莱®)Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan). To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy. Sac-TMT became the first domestic ADC with global intellectual property rights to be fully approved for marketing. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic HR+/HER2- BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the CDE, and were included in the priority review and approval process. As of today, the Company has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab2 or other agents for several types of cancer. These studies are sponsored and led by MSD. About Tagitanlimab (科泰莱®)Tagitanlimab is the first PD-L1 mAb globally to receive authorization for the first-line treatment of NPC. Previously, the NMPA has approved the marketing in China of tagitanlimab used in combination with cisplatin and gemcitabine for the first-line treatment of patients with R/M NPC and monotherapy for the treatment of patients with recurrent or metastatic NPC who have failed after prior 2L+ chemotherapy, respectively. About Kelun-BiotechKelun-Biotech ( is a holding subsidiary of Kelun Pharmaceutical ( which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit Media: klbio_pr@ View original content to download multimedia: SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
